These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37538343)

  • 1. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.
    Clark ED; Perin J; Herrmann N; Brawman-Mintzer O; Lanctôt KL; Lerner AJ; Mintzer J; Padala PR; Rosenberg PB; Sami S; Shade DM; van Dyck CH; Porsteinsson AP;
    Alzheimers Dement (N Y); 2023; 9(3):e12403. PubMed ID: 37538343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
    Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
    Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.
    Lanctôt KL; Scherer RW; Li A; Vieira D; Coulibaly H; Rosenberg PB; Herrmann N; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer JE
    Am J Geriatr Psychiatry; 2021 Jan; 29(1):81-89. PubMed ID: 32565008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
    Mintzer J; Lanctôt KL; Scherer RW; Rosenberg PB; Herrmann N; van Dyck CH; Padala PR; Brawman-Mintzer O; Porsteinsson AP; Lerner AJ; Craft S; Levey AI; Burke W; Perin J; Shade D;
    JAMA Neurol; 2021 Nov; 78(11):1324-1332. PubMed ID: 34570180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
    Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
    J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological interventions for apathy in Alzheimer's disease.
    Ruthirakuhan MT; Herrmann N; Abraham EH; Chan S; Lanctôt KL
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012197. PubMed ID: 29727467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.
    Lanctôt KL; Rivet L; Tumati S; Perin J; Sankhe K; Vieira D; Mintzer J; Rosenberg PB; Shade D; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey AI; Padala KP; Herrmann N
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1077-1087. PubMed ID: 37385898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia.
    Siafarikas N; Alnæs D; Monereo-Sanchez J; Lund MJ; Selbaek G; Stylianou-Korsnes M; Persson K; Barca ML; Almdahl IS; Fladby T; Aarsland D; Andreassen OA; Westlye LT
    Int Psychogeriatr; 2021 Nov; 33(11):1217-1228. PubMed ID: 34399870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies.
    Lee CW; Chen JY; Ko CC; Chuang MH; Tsai WW; Sun CK; Hung KC
    Psychopharmacology (Berl); 2022 Dec; 239(12):3743-3753. PubMed ID: 36243827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development.
    Burke SL; Maramaldi P; Cadet T; Kukull W
    Arch Gerontol Geriatr; 2016; 65():231-8. PubMed ID: 27111252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
    Lanctôt KL; Chen C; Mah E; Kiss A; Li A; Shade D; Scherer RW; Vieira D; Coulibaly H; Rosenberg PB; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer J; Herrmann N
    Int Psychogeriatr; 2023 Nov; 35(11):664-672. PubMed ID: 37066690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
    Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
    BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Padala PR; Padala KP; Lensing SY; Ramirez D; Monga V; Bopp MM; Roberson PK; Dennis RA; Petty F; Sullivan DH; Burke WJ
    Am J Psychiatry; 2018 Feb; 175(2):159-168. PubMed ID: 28945120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric Symptoms of Alzheimer's Disease in Down Syndrome and Its Impact on Caregiver Distress.
    Fonseca LM; Mattar GP; Haddad GG; Burduli E; McPherson SM; Guilhoto LMFF; Yassuda MS; Busatto GF; Bottino CMC; Hoexter MQ; Chaytor NS
    J Alzheimers Dis; 2021; 81(1):137-154. PubMed ID: 33749644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life in relation to neuropsychiatric symptoms in Alzheimer's disease: 5-year prospective ALSOVA cohort study.
    Hongisto K; Hallikainen I; Selander T; Törmälehto S; Väätäinen S; Martikainen J; Välimäki T; Hartikainen S; Suhonen J; Koivisto AM
    Int J Geriatr Psychiatry; 2018 Jan; 33(1):47-57. PubMed ID: 28067961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease.
    Andrade C
    J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35120284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study.
    Vik-Mo AO; Giil LM; Ballard C; Aarsland D
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1361-1369. PubMed ID: 29979473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.
    Lanctôt KL; Chau SA; Herrmann N; Drye LT; Rosenberg PB; Scherer RW; Black SE; Vaidya V; Bachman DL; Mintzer JE
    Int Psychogeriatr; 2014 Feb; 26(2):239-46. PubMed ID: 24169147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of caregiver demographic variables with neuropsychiatric symptoms in Alzheimer's disease patients for distress on the Neuropsychiatric Inventory (NPI).
    Godinho C; Camozzato A; Kochhann R; Chaves MLF
    Dement Neuropsychol; 2008; 2(3):211-216. PubMed ID: 29213573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.